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Background: Estrogen metabolism may be associated with the pathophysiological development of papillary
thyroid carcinoma (PTC).
Methods: To evaluate the differential estrogen metabolism between benign and malignant PTCs, estrogen profiling
by gas chromatography–mass spectrometry was applied to urine samples from postmenopausal patients with 9
benign tumors and 18 malignant stage I and III/IV PTCs.
Results: The urinary concentration of 2-methoxyestradiol was significantly lower in the stage I malignant patients
(3.5-fold; P < 0.025) than in the benign group. The metabolic ratios of 16α-OH-estrone/estrone and estriol/estradiol,
which are responsible for 16α-hydroxylase activity, were increased more than 2.5-fold in the advanced-stage
malignant PTC (P < 0.02 each). The more than 6.2-fold decrease in the urinary 2-/16α-hydroxylase ratio in stage III/IV
malignant PTC was consistent with the ratio in postmenopausal patients with endocrine gland cancers. In addition,
reductive 17β-hydroxysteroid dehydrogenase (17β-HSD; estradiol/estrone or estriol/16α-OH-estrone) was present at
significantly higher levels in subjects with stage III/IV malignant PTCs than in benign subjects (>3.5-fold difference;
P < 0.002). In particular, the estriol/16α-OH-estrone ratio differentiated between the benign and early-stage
malignant patients (P < 0.01).
Conclusions: Increased 16α-hydroxylation and/or a decreased 2-/16α-ratio, as well increased reductive 17β-HSD,
with regard to estrogen metabolism could provide potential biomarkers. The devised profiles could be useful for
differentiating malignant thyroid carcinomas from benign adenomas in postmenopausal women.
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Papillary thyroid carcinoma (PTC), the most frequently
occurring thyroid carcinoma, is a well-differentiated
endocrine-based tumor [1] with a 3-fold higher inci-
dence in women than in men [2]. The identification of
thyroid nodule malignancy is based on ultrasonography,
scintigraphy, and fine-needle aspiration biopsy (FNAB)
[3]. However, the results are limited to the differentiation
of benign adenomas (adenomatous hyperplasia) from ma-
lignant thyroid carcinomas [4]. Because the prognosis is
strongly determined by the tumor stage at diagnosis and* Correspondence: mh_choi@kist.re.kr
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reproduction in any medium, provided the orthe initial treatment, regardless of the patient age and
histological type (especially in postmenopausal women)
[5], novel and reliable biomarkers for early-stage diagnosis
of thyroid malignancy that could noninvasively discrimin-
ate between malignant and benign nodules are necessary.
The identification of potential gene or protein expres-
sion markers for benign/malignant classifications was per-
formed in vitro and in vivo using immunohistochemistry,
Western blotting [6,7], or multi-gene approaches with
microarray technology and molecular profiling of thyroid
tissues from FNABs [8-10]. In recent, the pathophysio-
logical roles of estrogen metabolism have been investi-
gated with regard to human thyroid gland development
[11-13], and estrogen metabolic alterations have beentd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sex differences and menopausal conditions [14].
Estrogens are involved in the pathogenesis of thyroid
nodules and differentiated thyroid cancer cells [15].
Benign and malignant thyroid cells and tissues express
functional estrogen receptors (ERs), and their growth is
stimulated by estrogen. In addition, estrogen can stimu-
late the growth and simultaneously inhibit the differenti-
ation of thyroid nodule-derived stem/progenitor cells
[16], which are adult stem cells that have been suggested
as an alternative source of benign and malignant tumor
formation [17]. There are 2 main estrogen metabolic path-
ways: the first is 16α-hydroxylation, which produces both
estriol (16α-hydroxyestradiol) and 16α-hydroxyestrone,
and the second is 2- and/or 4-hydroxylation to form 2-
and 4-catechol estrogens [18,19]. In general, women with
increased 16α-hydroxylation are thought to have an ele-
vated risk of breast cancer, compared with women with
increased 2-hydroxylation estrogen metabolism [20-23].
Thus, a decreased 2- to 16α-hydroxylation ratio has been
shown to precede clinical evidence of cancer and therefore
represents a significant risk factor for estrogen-dependent
tumor development. However, the pathogenic differences
in estrogen metabolism between benign and malignant
thyroid tumors have not been fully explored, especially in
postmenopausal women.
Gas chromatography–mass spectrometry (GC-MS)-
based steroid profiling is a powerful technique that not
only can describe risk associations and relationships
between steroid hormones and clinical tumor growth
characteristics but can also be used as a biomarker tool
for discriminating benign from malignant adrenal tu-
mors [24,25]. For low-level quantification, we developed
a comprehensive urinary estrogen profile from osteopor-
otic postmenopausal women [26]. The aim of this study
was to assess the differential expression of estrogen me-
tabolites and their metabolic ratios between benign
adenoma and malignant PTC patients to elucidate the
underlying mechanisms of thyroid cancer pathology, as
well as to identify potent biomarkers that are predictive
of clinical characteristics. In addition, our results address
the issue of whether preferential downregulation of the
2-/16α-hydroxylation ratio in postmenopausal women
with thyroid malignancies could provide a useful presur-
gical classification for determining malignancy in thyroid
carcinomas, as in other endocrine gland cancers.
Methods
Subjects and sample collection
Urine samples were collected from postmenopausal pa-
tients with a total of 18 malignant PTCs, including 11
women diagnosed with stage I (age: 56.1 ± 3.7 yr, body
mass index [BMI]: 26.0 ± 3.3 kg/m2) and 7 women diag-
nosed with stage III/IV disease (age: 59.6 ± 10.9 yr, BMI:22.9 ± 2.7 kg/m2) at Severance Hospital (Seoul, Korea).
In addition, samples from 9 women diagnosed with
benign tumors (adenomatous hyperplasia; age: 59.2 ±
5.8 yr, BMI: 26.5 ± 3.8 kg/m2) were included as a control
group. All the subjects underwent the same diagnostic
procedures, including a pathological examination, ultra-
sonography, and FNAB, as detailed by the American
Joint Committee on Cancer staging criteria [3]. Patients
with a history of cervical, breast, endometrial, or head and
neck cancer and those with a history of respiratory papil-
lomatosis were excluded. All the subjects had normal
thyroid function (T3: 104.11 ± 19.1 ng/dL, T4: 11.16 ±
2.56 μg/dL, and TSH: 1.02 ± 0.31 μIU/mL) and were not
treated with or exposed to any drugs or exogenous hor-
mones for defined time periods. The experimental proto-
col (no. 4-2009-0424) was approved by the Institutional
Review Board (IRB) Committee of the Human Research
Protection Center at Severance Hospital, and informed
written consent was obtained from all the subjects. All
urine samples were collected in the morning after 12 h of
fasting and immediately stored at −20°C until used. The
urinary steroid levels were calibrated with creatinine
values, according to Jaffé’s method [27].
Chemicals and materials
Reference standards of the 16 estrogens, including es-
trone (E1), 17β-estradiol (E2), estriol (E3), 2-hydroxyes-
trone (2-OH-E1), 2-hydroxy-17β-estradiol (2-OH-E2),
4-hydroxyestrone (4-OH-E1), 4-hydroxy-17β-estradiol
(4-OH-E2), 2-methoxyestrone (2-MeO-E1), 2-methoxy-
17β-estradiol (2-MeO-E2), 4-methoxyestrone (4-MeO-
E1), 4-methoxy-17β-estradiol (4-MeO-E2), 17-epiestriol
(17-epi-E3), 16-epiestriol (16-epi-E3), 16α-hydroxyes-
trone (16α-OH-E1), 16-keto-17β-estradiol (16-keto-E2),
and 2-hydroxyestriol (2-OH-E3), were obtained from
Steraloids (Newport, RI, USA). A deuterium-labeled in-
ternal standard (IS), 2,4,16,16-d4-17β-estradiol (d4-E2,
isotopic purity ≥ 98%), was purchased from C/D/N Iso-
topes (Pointe-Claire, Quebec, Canada).
In solid-phase extraction (SPE), Oasis HLB (3 cc,
60 mg; Waters, Milford, MA, USA) preconditioned with
2 mL of methanol, followed by 2 mL of deionized water
was used. Sodium acetate (reagent grade), acetic acid (gla-
cial, 99.99 + %), and L-ascorbic acid (reagent grade) were
acquired from Sigma (St. Louis, MO, USA). A solution of
β-glucuronidase/arylsulfatase from Helix pomatia was
purchased from Roche Diagnostics GmbH (Mannheim,
Germany). Anhydrous potassium carbonate (K2CO3),
triethylamine (TEA), and ethyl chlorofomate (ECF) were
obtained from J. T. Baker (Phillipsburg, NJ, USA), Sigma,
and Daejung Chemical Co. (Shiheung, Gyoungi, Korea),
respectively. The perfluoroacylation reagent, pentafluoro-
propionic anhydride (PFPA), was also obtained from
Sigma. All organic solvents used were analytical and
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Jackson (Muskegon, MI, USA). Deionized water was
prepared with a Milli-Q purification system (Millipore,
Billerica, MA, USA).
GC-MS-based quantitative estrogen profiling
Quantitative estrogen profiling was performed according
to a previous technique [26]. Briefly, the urine sample
(2 mL) containing 100 μL of 0.2% aqueous L-ascorbic
acid was spiked into 15 μL of the internal standard d4-
E2 (1 μg/mL). The samples were extracted with Oasis
HLB SPE cartridges that were placed into a device fitted
with a small peristaltic pump that was operated at a flow
rate < 1 mL/min. After loading each sample into a cart-
ridge, the cartridges were washed with 2 mL of water
and eluted twice with 2 mL of methanol. The combined
methanol was evaporated under a nitrogen stream and
then added to 1 mL of 0.2 M acetate buffer (pH 5.2),
100 μL of aqueous 0.2% L-ascorbic acid, and 50 μL of β-
glucuronidase/arylsulfatase. After a 3-h incubation at
55°C, the solution was adjusted to pH 8 with a 5%
K2CO3 solution, and then 30 μL of TEA and 50 μL of
ECF were added. After vortexing for 30 s, the sample
was extracted twice with 2.5 mL of a nonpolar solvent
(n-hexane). The organic solvent was evaporated in an
N2 evaporator at 40°C, and the sample was dried in a
vacuum desiccator over P2O5-KOH for at least 30 min.
Finally, the dried residue was derivatized with 20 μL of
PFPA in 100 μL of n-hexane at 50°C for 30 min and
then evaporated in an N2 evaporator. Two microliters of
the resulting product, reconstituted with 40 μL of n-
hexane, were injected for GC-MS analysis with the
selected-ion monitoring (SIM) mode.
The GC-SIM/MS was performed on an Agilent 6890 Plus
gas chromatograph interfaced with a single-quadrupole
Agilent 5975C MSD. The electron energy was 70 eV, and
the ion source temperature was 230°C. Each sample (2 μL)
was injected in split mode (10:1) at 280°C and separated
through an MXT-1 cross-linked dimethylpolysiloxane
capillary column (30-m × 0.25-mm I.D., 0.25-μm film
thickness, Silcosteel-treated stainless steel). The initial
oven temperature was 270°C, which was increased to
300°C at 6°C/min, and finally increased to 330°C with a
10°C/min ramping program. The column head pressure,
with helium as the carrier gas, was set to 151.7 kPa. The
calibration curve consisted of a blank sample and 11
samples from LOQ. This method was linear, with a cor-
relation coefficient (r2 > 0.996) for all estrogens ana-
lyzed, and the intraday coefficients of variation ranged
from 1.3% to 7.7%.
Statistical analysis
Data manipulation was performed with SigmaPlot (Systat
Software Inc., San Jose, CA, USA) and the SPSS (v. 21) forWindows software package (SPSS Inc., Chicago, IL, USA).
The concentrations of the individual estrogens and meta-
bolic ratios were calculated by dividing the substrate
concentration by that of its metabolite (as an indicator
of enzyme activity) in the urine samples obtained from
postmenopausal women. Statistical significance was
determined with nonparametric Kruskal-Wallis and
Mann–Whitney U tests to evaluate possible differences
in the diagnostic factors. The significant variables with
P < 0.05 in the Kruskal-Wallis test were then compared
with Mann–Whitney U tests between 2 groups, includ-
ing benign versus stage I PTC, benign versus stage III/
IV PTC, and stage I versus stage III/IV PTC. A Bonferroni
correction was used to adjust for the 2 comparisons
performed on each variable and to set the significance
level at 0.017. The concentration of estrogens was listed in
Supplementary Data as an Additional file 1.
Results
Urinary concentrations of estrogens in patients with
benign and malignant tumors
The individual urinary estrogen levels in the postmeno-
pausal women with benign and malignant tumors were
evaluated. Among the 16 estrogens monitored, 15 estro-
gens, including parent estrogens (E1 and E2), 16α-
hydroxylation metabolites (16α-OH-E1, 16-keto-E2, E3
[16α-OH-E2], 17-epi-E3, and 16-epi-E3), 2- and 4-hydro
xylation metabolites (2-OH-E1, 2-OH-E2, 4-OH-E1, and
4-OH-E2), and 2- and 4-methoxylation metabolites (2-
MeO-E1, 2-MeO-E2, 4-MeO-E1, and 4-MeO-E2), were
quantitatively detected (Table 1). No 2-OH-E3 was de-
tected in this study.
To characterize the differential excretion patterns of
postmenopausal malignant thyroid carcinoma patients
according to the tumor stage, samples were analyzed
from the patients diagnosed at early (stage I) and ad-
vanced (stage III/IV) stages, and the samples from each
group were compared with the control benign samples.
Differences in the concentrations of 2-MeO-E2, 4-MeO-
E1, and 17-epi-E3 were statistically significant between
the benign and stage I malignant tumors. The urinary
levels of these substances were found to be significantly
reduced in stage I malignant PTCs (P < 0.02); in particu-
lar, the levels of 2-MeO-E2 and 4-MeO-E1 in early-stage
malignant patients were >3.5-fold (P = 0.012) and >6.0-
fold (P = 0.004) lower than those in the benign samples.
There were no statistically significant differences be-
tween the malignant PTCs stages.
Metabolic alterations with benign tumors and malignant
PTCs
Based on the individual concentrations, the metabolite to
precursor ratios, which could be used to gain insight into
metabolic enzyme activity, were examined to understand
Table 1 Urinary estrogen concentrations associated with benign tumors and malignant Papillary Thyroid Carcinomas
(PTCs) in the postmenopausal women
Compounds (trivial name) Benign tumor
(a) (n = 9)
Malignant PTCs P-value2
Stage I (b) (n = 11) Stage III/IV (C) (n = 7) P-value1 a vs. b a vs. c b vs. c
Estrone (E1) 12.1 ± 11.3 2.9 ± 2.3 5.0 ± 6.5 0.053 0.020 0.091 0.791
17β-estradiol (E2) 0.8 ± 0.6 0.4 ± 0.2 1.1 ± 1.3 0.416
Estriol (E3) 1.7 ± 1.7 1.9 ± 1.7 6.2 ± 6.7 0.146
2-hydroxyestrone (2-OH-E1) 2.2 ± 3.5 0.3 ± 0.3 0.7 ± 1.2 0.073
2-hydroxy-17β-estradiol (2-OH-E2) 0.5 ± 0.4 0.1 ± 0.1 0.3 ± 0.2 0.052 0.031 0.536 0.085
4-hydroxyestrone (4-OH-E1) 0.6 ± 0.5 0.3 ± 0.3 0.4 ± 0.4 0.558
4-hydroxy-17β-estradiol (4-OH-E2) 0.5 ± 0.4 0.1 ± 0.1 0.2 ± 0.1 0.182
2-methoxyestrone (2-MeO-E1) 1.6 ± 1.7 0.5 ± 0.4 0.6 ± 0.6 0.108
2-methoxy-17β-estradiol (2-MeO-E2) 1.4 ± 1.1 0.4 ± 0.3 0.6 ± 0.4 0.034 0.012 0.114 0.285
4-methoxyestrone (4-MeO-E1) 0.6 ± 0.8 0.1 ± 0.1 0.2 ± 0.4 0.011 0.004 0.174 0.179
4-methoxy-17β-estradiol (4-MeO-E2) 0.3 ± 0.7 0.1 ± 0.1 0.2 ± 0.2 0.104
17-epiestriol (17-epi-E3) 0.3 ± 0.3 0.1 ± 0.1 0.1 ± 0.1 0.029 0.016 0.142 0.425
16-epiestriol (16-epi-E3) 0.7 ± 0.9 0.3 ± 0.2 0.9 ± 1.0 0.589
16α-hydroxyestrone (16α-OH-E1) 0.9 ± 0.7 0.6 ± 0.6 0.8 ± 0.8 0.462
16-keto-17β-estradiol (16-keto-E2) 0.7 ± 0.9 0.6 ± 0.6 0.7 ± 1.0 0.803
Concentrations are expressed as ng/mg of creatinine (mean ± SD).
Statistical significance was determined by a nonparametric 1Kruskal-Wallis and 2Mann-Whitney U test to evaluate possible differences in the diagnostic factors.
The significant estrogens with P < 0.05 in a Kruskal-Wallis test were then compared with the Mann–Whitney U test results between 2 groups, including benign
versus stage I PTC (a vs. b), benign versus stage III/IV PTC (a vs. c), and stage I versus stage III/IV PTC (b vs. c). A Bonferroni correction was applied to the post hoc
analysis of the between-group comparisons performed for each variable and to set the significance level at 0.017.
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roid tumors (Table 2). In contrast to the individual con-
centrations, significant changes between the patients with
benign tumors and those with malignant PTCs, with
either stage I or III/IV diagnosis, were confirmed by the
differences in these metabolic ratios. For 16α-hydroxylase,
the ratios of 16α-OH-E1 to E1 (Figure 1A) and E3 to E2
(Figure 1B) were significantly higher in patients with stage
III/IV malignant PTCs than in those with benign tu-
mors (P < 0.02 each). There were no significant changes
in the metabolic activity of 4-hydroxylase of estrogens
and catechol-O-methyltransferase of 2 and 4-hydroxy
estrogens.
Reductive 17β-hydroxysteroid dehydrogenase (17β-
HSD), which converts E1 into E2 and 16α-OH-E1 into
E3 by reduction at the C17 position [19], was signifi-
cantly different in samples from patients with malignant
PTCs and those from patients with benign tumors
(Figure 1C-D). The ratios of E2 to E1 (P = 0.046 for be-
nign vs. stage I; P = 0.002 for benign vs. stage III/IV,
Figure 1C) and of E3 to 16α-OH-E1 (P = 0.010 for be-
nign vs. stage I; P = 0.0001 for benign vs. stage III/IV,
Figure 1D) could differentiate benign from malignant
tumor samples. In addition, a significant reduction in
urinary 2-/16α-hydroxylation pathway was observed in pa-
tients with stage III/IV malignant PTC, compared withthose with benign tumors (>6.2-fold difference; P = 0.012;
Figure 1E).
Discussion
Over the last decades, many studies based on gene or
protein expression in vitro and in vivo have evaluated
the role of biomarkers in determinations of thyroid
tumor malignancy [6-10], but candidate biomarkers such
as galectin-3 or MET have not shown the sensitivity and
specificity needed for a preoperative thyroid nodules
screening tool [28]. We previously evaluated metabolic
changes in urinary steroid levels in premenopausal and
postmenopausal women and men with PTCs by quanti-
tative steroid profiling, as PTC pathogenesis and devel-
opment might be affected by androgens and estrogens
[14]. However, these results did not reveal information
about the changes in estrogen metabolism that could
distinguish PTCs from benign thyroid tumors. Therefore,
this study focused more on the metabolic differences
between benign tumors and early and advanced-stage ma-
lignant PTCs in postmenopausal women.
The 2-MeO-E2 levels significantly decreased in both
early and advanced PTCs, suggesting that this could
serve as a potential biomarker to differentiate benign
from malignant thyroid neoplasms. 2-MeO-E2, which
acts as a potential antitumor agent in several types of
Table 2 Metabolic ratios of urinary estrogens between benign tumors and malignant Papillary Thyroid Carcinomas
(PTCs) in postmenopausal women
Metabolic ratio (product/precursor) Benign tumor
(a) (n = 9)
Malignant PTCs P-value2
Stage I (b) Stage III/IV (c) P-value1 a vs. b a vs. c b vs. c
(n = 11) (n = 7)
2-hydroxylase
2-OH-E1/E1 0.16 ± 0.14 0.13 ± 0.09 0.16 ± 0.15 0.991
2-OH-E2/E2 0.75 ± 0.40 0.38 ± 0.30 0.47 ± 0.29 0.070
4-hydroxylase
4-OH-E1/E1 0.10 ± 0.13 0.12 ± 0.09 0.15 ± 0.08 0.182
4-OH-E2/E2 0.64 ± 0.44 0.42 ± 0.28 0.40 ± 0.20 0.360
16α-hydroxylase
16α-OH-E1/E1 0.12 ± 0.09 0.26 ± 0.20 0.31 ± 0.20 0.052 0.095 0.012 0.659
E3/E2 2.16 ± 1.10 4.72 ± 3.28 6.66 ± 3.27 0.007 0.067 0.001 0.126
Methyltransferase
2-MeO-E1/2-OH-E1 1.43 ± 0.94 1.68 ± 1.00 1.66 ± 0.93 0.838
2-MeO-E2/2-OH-E2 6.35 ± 8.80 4.98 ± 5.47 3.55 ± 4.53 0.935
4-MeO-E1/4-OH-E1 3.23 ± 6.88 0.25 ± 0.18 0.58 ± 0.47 0.140
4-MeO-E2/4-OH-E2 4.02 ± 7.28 0.83 ± 0.57 1.20 ± 0.60 0.216
17β-hydroxysteroid dehydrogenase
E2/E1 0.10 ± 0.08 0.23 ± 0.22 0.26 ± 0.08 0.013 0.046 0.002 0.285
E3/16α-OH-E1 1.75 ± 0.80 3.79 ± 1.80 6.15 ± 2.18 0.001 0.010 0.0001 0.044
2-/16α-hydroxylation
2-OH-E1/16α-OH-E1 2.05 ± 2.46 0.82 ± 0.74 0.64 ± 0.58 0.110
2-OH-E2/E3 0.50 ± 0.46 0.11 ± 0.14 0.08 ± 0.06 0.022 0.020 0.012 0.930
The metabolic ratios are presented as the metabolite-to-precursor ratio in each subject (mean ± SD).
Statistical significance was determined with nonparametric 1Kruskal-Wallis and 2Mann-Whitney U tests to evaluate possible differences in the diagnostic factors.
The significant metabolic ratios with P < 0.05 in the Kruskal-Wallis test were then compared with the Mann–Whitney U test between 2 groups, including benign
versus stage I PTC (a vs. b), benign versus stage III/IV PTC (a vs. c), and stage I versus stage III/IV PTC (b vs. c). A Bonferroni correction was applied to the post hoc
analysis of the between-group comparisons performed for each variable and to set the significance level at 0.017.
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tosis in thyroid carcinoma cells by activating the p38
mitogen-activated protein kinase [31]. Based on its cel-
lular effects, 2-MeO-E2 might be expected to attenuate
the progression of tumorigenesis and protect against the
development of malignant PTCs from benign adenomas.
Estrogen metabolism was shown to potentiate the
growth of several cancers, including breast, prostate,
endometrial, and thyroid cancers [12-14,20-23,25,31].
For E2, the C-2/C-16α-hydroxylation ratio and level of
16α-hydroxylation could be used as predictive biomarkers
for breast cancer [20-22], suggesting that the major estro-
gen metabolism pathways have different biological actions
such as the antiproliferative effect of 2-hydroxylation and
proliferative effect of 16α-hydroxylation in hormone-
related cancers [12,18-23]. In this study, 16α-hydroxylation
of both E1 and E2 was markedly increased in both early
and advanced-stage malignant PTCs. In particular, the in-
fluence of estrogen 16α-hydroxylation tended to be in clear
contrast to that of 2-hydroxylation in postmenopausal low-
and high-grade PTCs (Table 2).Increased 16α-hydroxylation activity preceded clinical
evidence of cancer and therefore might represent a
significant risk factor for estrogen-dependent tumor de-
velopment [20-23]. In this study, the 2-OH-E1-to-16α-
OH-E1 ratio was not statistically significantly different
between the malignant PTC and benign groups, despite
the lower activity in the former group. However, a de-
creased 2-OH-E2-to-E3 ratio was observed. For E2, the
ratio of C-2 and C-16α hydroxylation in the malignant
PTC groups might reflect the observed effects of in-
creased 16α-hydroxylation on malignant PTC in post-
menopausal women. This observation is consistent with
previous studies that examined the extent of the inter-
play between 2-hydroxylation and 16α-hydroxylation
and reflected that the estrogen metabolite ratio could be
a distinguishing feature between benign and malignant
thyroid tumors [12].
Another interesting estrogen profile pattern was de-
tected between the benign and malignant tumors. The ex-
pression of reductive 17β-HSD in patients with both early
and late-stage PTCs was significantly higher than that in
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Figure 1 Differential metabolic ratios on estrogen metabolism with statistical significance in benign and malignant papillary thyroid
tumors. Estrogen activities were compared in postmenopausal women with benign adenomas (n = 9) and stage I (n = 11) and III/IV (n = 7)
malignant carcinomas. The significant metabolic ratios with P < 0.05 in a Kruskal-Wallis test were analyzed with the Mann–Whitney U test
between 2 groups, including benign versus stage I PTC, benign versus stage III/IV PTC, and stage I versus stage III/IV PTC. (A) 16α-OH-E1/E1,
(B) E3/E2, (C) E2/E1, (D) E3/16α-OH-E1 and (E) 2-OH-E2/E3. * P < 0.02; ** P < 0.002; and *** P < 0.0002.
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E2 and 16α-OH-E1 to E3 (Table 2). Although the under-
lying mechanism is not clear, the E3-to-16α-OH-E1 ratio
progressively increased from the benign group to the early
stage malignant PTC group and finally to the advanced-
stage malignant PTC group, and had a more significant P
value than the E2 to E1 ratio. In recent, the implications
of 17β-HSD activity in tumorigenesis have been investi-
gated [32-34]. In these studies, high 17β-HSD activity was
related to increased cell proliferation, and it was important
to the understanding of the mechanisms that underlie
breast cancer development [32,33]. Reductive 17β-HSD is
also overexpressed in endometrial cancer, compared with
control tissues, and was found to increase tumor cell pro-
liferation [34]. To our knowledge, this is the first study to
demonstrate an association between 17β-HSD expression
and pathological features in patients with PTCs.
This study had 2 limitations. First, a small number of
postmenopausal women with thyroid disease (only 27
individuals) limited the statistical power with which to
distinguish between benign and malignant tumors. Des-
pite these drawbacks, however, very few fundamental
studies on this topic have been performed in postmeno-
pausal women. Although we could not conclusively de-
termine the associations between estrogen metabolism
and pathological features in patients with PTCs, we havedemonstrated statistically significant estrogen metabolic
patterns and differentiated metabolic pathways. Second,
high variability in the urinary estrogen levels was de-
tected in all postmenopausal patients, including those of
advanced age. Most circulating estrogens in elderly
women are derived from adipose tissues and can be af-
fected by additional factors such as nutrition, smoking,
alcohol intake, and physical activity [35]. There is con-
siderable intra- and inter-patient estrogen variability
among postmenopausal women in response to estrogen
replacement therapy [36]. In contrast to the metabolic
ratios, the urinary levels of the individual estrogens, ex-
cept 2-MeO-E2, were not significantly different between
benign and malignant thyroid tumor patients because of
the high variability in the urinary estrogen levels. Further
studies with a large population of individuals with thy-
roid tumors are needed to better define the changes in
individual estrogens in PTC patients.
Conclusions
Malignant PTCs can be distinguished from benign thy-
roid nodules by urinary estrogen profiling. These obser-
vations suggest that activation of the 16α-hydroxylation
pathway and reductive 17β-HSD expression are import-
ant endocrine factors in thyroid tumorigenesis, similar
to their roles in other endocrine-related cancers such as
Moon et al. BMC Clinical Pathology 2013, 13:25 Page 7 of 8
http://www.biomedcentral.com/1472-6890/13/25breast and endometrial cancers. These results could
provide insights into the pathogenesis of PTC and might
ultimately describe a useful potent biomarker for prog-
nostic evaluations of malignant PTC in clinical practice
and for therapeutic management in patients with thy-
roid tumors.
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